Loading...
Loading...
ANIX| Name | Value |
|---|---|
| Revenues | 2,469.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 2,469.0M |
| Operating Expense | 3.6M |
| Operating I/L | -3.6M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.1M |
| Pretax | -3.5M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -3.4M |
Anixa Biosciences, Inc. is a biotechnology company specializing in the development of therapies and vaccines for oncology and infectious diseases. The company's revenue streams are derived from its therapeutic programs, including the development of chimeric endocrine receptor T-cell technology for ovarian cancer treatment, and the discovery of anti-viral drug candidates for COVID-19. Additionally, its vaccine programs focus on creating vaccines against triple negative breast cancer and ovarian cancer. Anixa Biosciences, Inc. also generates income from its collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19.
